Danish and Belgian biotech firms in licensing agreement  

Denmark's Exiqon and Belgium's Eurogentec group have agreed a licensing deal for Exiqon’s Locked Nucleic Acid technology

The Danish biotech company Exiqon and the Belgium-based Eurogentec group have announced the signing of a license agreement for Exiqon’s Locked Nucleic Acid (LNA) technology, reports biotechdenmark.dk. Under the terms of the agreement, Eurogentec has acquired non-exclusive rights to manufacture and sell LNA oligonucleotides and services for the genomics research market and will receive from Exiqon the know-how regarding LNA as well as raw materials. Financial terms of the agreement were not disclosed.


Exiqon is a privately held company located in Medicon Valley near Copenhagen. The company's main commercial strategy is out-licensing and partnering, and LNA is one of Exiqon's unique proprietary technologies. Eurogenic was founded in 1985 as a spin off from the University of Liège, and specialises in oligonucleotide and peptide synthesis, DNA sequencing, monoclonal and polyclonal antibody production, DNA array and transgenic services.


In May 2002, a delegation of Danish biotech companies met Belgian counterparts at a conference in Brussels, as part of a state visit to Belgium by Her Majesty Queen Margrethe and HRH Prince Henrik.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×